Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...

Clayton Dubilier & Rice is discussing the possibility of using borrowed money to fund a part of the equity check in its bid ...

An ambitious project that was hatched during the coronavirus pandemic has hit a key milestone as Sanofi has completed construction of Modulus, a vaccine and biological medicine plant that can be ...

Panacea Biotec announced that it has reached a settlement with Sanofi Healthcare over a patent infringement litigation ...

Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a ...

Sanofi agreed to pay up to 320 million euros ($352.4 million) to U.S. company RadioMedix and the biotechnology subsidiary of nuclear-fuel supplier Orano to license a potential treatment for rare ...

Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with ...

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

Sanofi (SNYNF, SNY) said it is shipping BEYFORTUS 50mg and 100mg Injection doses in the US to private healthcare providers and to the ...

Panacea Biotec has reached a settlement with Sanofi Healthcare India concerning a patent infringement for its fully liquid ...